These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15210526)

  • 1. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
    Rundek T; Naini A; Sacco R; Coates K; DiMauro S
    Arch Neurol; 2004 Jun; 61(6):889-92. PubMed ID: 15210526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
    Päivä H; Thelen KM; Van Coster R; Smet J; De Paepe B; Mattila KM; Laakso J; Lehtimäki T; von Bergmann K; Lütjohann D; Laaksonen R
    Clin Pharmacol Ther; 2005 Jul; 78(1):60-8. PubMed ID: 16003294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
    Blanco-Colio LM; Martín-Ventura JL; Gómez-Guerrero C; Masramon X; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Egido J
    Eur J Pharmacol; 2008 May; 586(1-3):259-65. PubMed ID: 18374327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
    Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J;
    Am Heart J; 2007 May; 153(5):881-8. PubMed ID: 17452168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coenzyme Q 10 and cardiovascular risk factors in idiopathic sudden sensorineural hearing loss patients.
    Cadoni G; Scipione S; Agostino S; Addolorato G; Cianfrone F; Leggio L; Paludetti G; Lippa S
    Otol Neurotol; 2007 Oct; 28(7):878-83. PubMed ID: 17558340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study.
    Kawashiri MA; Nohara A; Tada H; Mori M; Tsuchida M; Katsuda S; Inazu A; Kobayashi J; Koizumi J; Mabuchi H; Yamagishi M
    Clin Pharmacol Ther; 2008 May; 83(5):731-9. PubMed ID: 17957184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
    Sanguigni V; Pignatelli P; Lenti L; Ferro D; Bellia A; Carnevale R; Tesauro M; Sorge R; Lauro R; Violi F
    Circulation; 2005 Feb; 111(4):412-9. PubMed ID: 15687128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
    Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Hérnandez G; Egido J;
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):168-74. PubMed ID: 17053166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance.
    Muraki A; Miyashita K; Mitsuishi M; Tamaki M; Tanaka K; Itoh H
    J Appl Physiol (1985); 2012 Aug; 113(3):479-86. PubMed ID: 22653988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review.
    Schwertz DW; Badellino KO
    J Cardiovasc Nurs; 2008; 23(1):8-13. PubMed ID: 18158500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.